• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Japan Diabetic Retinopathy Market

    ID: MRFR/HC/48707-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    Japan Diabetic Retinopathy Market Research Report By Type (Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR)), By Treatment (Pharmacological Therapies, Laser Treatment, Surgery), and By End-user (Hospitals & Clinics, Ophthalmology Centers, Research Institutes)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Japan Diabetic Retinopathy Market Research Report - Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Japan Diabetic Retinopathy Market Summary

    The Japan Diabetic Retinopathy market is projected to experience substantial growth from 362 USD Million in 2024 to 912 USD Million by 2035.

    Key Market Trends & Highlights

    Japan Diabetic Retinopathy Key Trends and Highlights

    • The market is expected to grow at a compound annual growth rate (CAGR) of 8.76% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 912 USD Million, indicating robust expansion.
    • In 2024, the market is valued at 362 USD Million, reflecting the current demand for diabetic retinopathy treatments.
    • Growing adoption of advanced diagnostic technologies due to increasing prevalence of diabetes is a major market driver.

    Market Size & Forecast

    2024 Market Size 362 (USD Million)
    2035 Market Size 912 (USD Million)
    CAGR (2025-2035) 8.76%

    Major Players

    Santen Pharmaceutical, Bayer, Novartis, Otsuka Pharmaceutical, Eli Lilly, AstraZeneca, Roche, Alcon, Chugai Pharmaceutical, Takeda Pharmaceutical, Samsung Bioepis, AbbVie, Pfizer, Hoffmann la Roche, Regeneron Pharmaceuticals

    Japan Diabetic Retinopathy Market Trends

    The Ministry of Health, Labour, and Welfare has noted that the country's expanding diabetes incidence is driving significant trends in the Japanese diabetic retinopathy market. Early detection and good management of diabetic retinopathy, a major cause of blindness among working-age adults in Japan, are more important as the number of people with diabetes diagnoses rises.

    This situation is a major market driver that forces technology firms and healthcare providers to embrace cutting-edge screening methods and creative treatment approaches. Additionally, telemedicine and mobile health applications are being developed to explore market prospects.

    These technologies make screening services more accessible, particularly in remote locations where there may be a shortage of medical experts. As more patients look for individualized treatment programs that address their unique needs, the emphasis on patient-centered care is also growing.

    Such programs, which promote research and cooperation among stakeholders in the healthcare industry, are being supported by the Japanese government. Artificial intelligence has been increasingly used into diabetic retinopathy diagnosis techniques in recent years.

    By enabling faster, more accurate assessments, these developments lessen the workload for ophthalmologists and increase the accuracy of imaging technologies. Effective disease management also much depends on the development of novel treatments, such as anti-VEGF injections.

    In a country marked by an ageing population and rising healthcare expenses, this modernisation is crucial to meeting the growing need for effective, efficient care solutions. All things considered, these patterns reflect a dynamic change in the Japanese market for diabetic retinopathy, which is being fuelled by the demand for improved technology and a more all-encompassing method of patient treatment.

    Market Segment Insights

    Diabetic Retinopathy Market Type Insights

    The Japan Diabetic Retinopathy Market is characterized by its crucial Type segmentation, which can be divided into Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR). This segmentation plays a vital role in addressing the increasing prevalence of diabetic retinopathy, a significant concern considering Japan's aging population and rising cases of diabetes.

    NPDR is notable for being the early stage of the disease, wherein the retina experiences no new blood vessel growth but may exhibit symptoms like microaneurysms and retinal hemorrhages. This stage is critical as timely detection and management can significantly alter the disease's trajectory, preventing progression to more severe forms.

    On the other hand, PDR represents a more advanced condition characterized by abnormal blood vessel proliferation, which can lead to serious complications like vision loss. The growing awareness of diabetic eye diseases and enhanced screening programs in Japan underline the significance of both NPDR and PDR.

    The continuous advancements in diagnostic technologies, along with the development of innovative treatment methods, support patient management effectively, addressing the needs of a substantial demographic suffering from diabetes.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Diabetic Retinopathy Market Treatment Insights

    The Treatment segment of the Japan Diabetic Retinopathy Market is crucial in addressing the increasing prevalence of this ocular complication among diabetic patients in Japan. Pharmacological Therapies are significant for managing symptoms and slowing disease progression, while Laser Treatment remains a primary choice due to its effectiveness in preventing severe vision loss.

    Surgery is often considered for advanced cases where previous treatments have failed, highlighting the critical role of each approach in the overall treatment landscape. The integration of new technologies and techniques in Laser Treatment and Surgical options is expected to enhance effectiveness, driving the market forward.

    As Japan continues to confront rising diabetes rates, the demand for effective treatment options will rise, emphasizing the importance of this segment in safeguarding visual health.

    The Japan Diabetic Retinopathy Market data indicates an increasing recognition of the unique needs of this demographic, calling for innovative solutions to mitigate the burden of diabetic retinopathy on patients and healthcare systems alike.

    With advancements in Research and Development, the Treatment segment is poised for significant growth, offering both challenges and opportunities in the evolving landscape of diabetic eye disease management.

    Diabetic Retinopathy Market End-user Insights

    The End-user segment of the Japan Diabetic Retinopathy Market reveals crucial insights into its structure and functionalities, dominating areas crucial for managing this ocular condition. Hospitals and Clinics serve as the primary settings for diagnosis and treatment, showcasing their essential role in providing comprehensive care and access to advanced therapeutic technologies.

    Ophthalmology Centers specialize in eye care, focusing solely on vision-related diseases, which positions them as significant players in screening and treatment techniques tailored to diabetic retinopathy. Research Institutes contribute by driving innovation through clinical research and studies aimed at improving treatment methods.

    In Japan, a rapidly aging population and increasing diabetes prevalence reinforce the importance of these End-users. Collectively, this segment reflects vital attributes of the Japan Diabetic Retinopathy Market, facilitating better healthcare delivery and improving patient outcomes.

    Get more detailed insights about Japan Diabetic Retinopathy Market Research Report - Forecast to 2035

    Key Players and Competitive Insights

    The Japan Diabetic Retinopathy Market is characterized by a competitive landscape that is evolving rapidly due to advancements in technology, a growing awareness of diabetic eye diseases, and the increasing prevalence of diabetes within the population.

    This market features a mix of established pharmaceutical companies and emerging firms, all striving to innovate and capture market share by developing better therapeutic options, treatment protocols, and diagnostic tools.

    Key players in the sector are continuously exploring collaborations, strategic partnerships, and mergers to enhance their product portfolios and improve patient outcomes. The competitive edge in this market heavily relies on R&D capabilities, market reach, and the ability to address unmet medical needs effectively.

    Santen Pharmaceutical has established a notable presence in the Japan Diabetic Retinopathy Market, primarily focusing on the development and commercialization of therapies targeting ocular diseases, including diabetic retinopathy.

    The company's strengths lie in its robust R&D framework dedicated to advancing therapeutic options for eye health, making it a crucial player in this sector. Santen Pharmaceutical excels in its commitment to innovation and the application of cutting-edge technologies, enabling the delivery of effective treatment modalities.

    Their localized understanding of the Japanese healthcare landscape ensures that their products meet specific regulatory requirements and patient needs, thereby enhancing trust and loyalty within the market.

    Bayer also holds a significant position in the Japan Diabetic Retinopathy Market, known for its contributions in the field of ophthalmology. The company's portfolio includes several key products aimed at treating diabetic retinopathy, reflecting its consistent focus on innovation and patient care.

    Bayer's strengths emerge from its extensive research capabilities, which allow for the development of advanced therapies and treatment protocols tailored to the Japanese population. The company has made significant investments in partnerships and collaborations to expand its reach and influence in this market further.

    Bayer's strong commitment to addressing diabetes-related vision problems is further highlighted through strategic mergers and acquisitions, bolstering its comprehensive offerings and enhancing its market presence. By leveraging its resources and expertise, Bayer aims to provide effective solutions that cater specifically to the needs of patients in Japan suffering from diabetic retinopathy.

    Key Companies in the Japan Diabetic Retinopathy Market market include

    Industry Developments

    The Japan Diabetic Retinopathy Market has witnessed significant developments recently, with a growing emphasis on innovative treatment options and advancements in technology. Notably, companies such as Santen Pharmaceutical and Bayer have been focusing on enhancing their product portfolios to address the increasing diabetes prevalence in Japan.

    In terms of recent mergers, Novartis announced the acquisition of a smaller biotech firm in July 2023 to broaden its capabilities in treating retinal diseases, aiming to strengthen its position in the diabetic retinopathy segment. Additionally, Eli Lilly's ongoing collaborations with local healthcare providers emphasize the importance of personalized therapy approaches and the integration of digital health solutions.

    As of October 2023, Roche and Regeneron Pharmaceuticals have contributed to rapid growth through their joint research initiatives exploring novel treatment pathways.

    The increasing incidence of diabetes-related complications has pushed the market valuation upward, prompting major companies like Otsuka Pharmaceutical and AstraZeneca to enhance their investment in Research and Development, enabling them to stay competitive.

    Over the last few years, the Japanese government has also been proactive in addressing diabetic retinopathy awareness, further solidifying the market’s potential.

    Market Segmentation

    Diabetic Retinopathy Market Type Outlook

    • Non-Proliferative Diabetic Retinopathy (NPDR)
    • Proliferative Diabetic Retinopathy (PDR)

    Diabetic Retinopathy Market End-user Outlook

    • Hospitals & Clinics
    • Ophthalmology Centers
    • Research Institutes

    Diabetic Retinopathy Market Treatment Outlook

    • Pharmacological Therapies
    • Laser Treatment
    • Surgery

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 344.8(USD Million)
    MARKET SIZE 2024 362.0(USD Million)
    MARKET SIZE 2035 912.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 8.763% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Santen Pharmaceutical, Bayer, Novartis, Otsuka Pharmaceutical, Eli Lilly, AstraZeneca, Roche, Alcon, Chugai Pharmaceutical, Takeda Pharmaceutical, Samsung Bioepis, AbbVie, Pfizer, HoffmannLa Roche, Regeneron Pharmaceuticals
    SEGMENTS COVERED Type, Treatment, End User
    KEY MARKET OPPORTUNITIES Aging population healthcare needs, Advanced screening technology adoption, Increased prevalence of diabetes, Rising awareness and education programs, Government funding for eye care initiatives
    KEY MARKET DYNAMICS aging population, increasing diabetes prevalence, advancements in treatment technologies, growing awareness campaigns, government healthcare initiatives
    COUNTRIES COVERED Japan

    FAQs

    What is the expected market size of the Japan Diabetic Retinopathy Market in 2024?

    The market is expected to be valued at 362.0 USD Million in 2024.

    What will be the projected market size of the Japan Diabetic Retinopathy Market by 2035?

    By 2035, the market is projected to reach a value of 912.0 USD Million.

    What is the expected compound annual growth rate (CAGR) for the Japan Diabetic Retinopathy Market from 2025 to 2035?

    The market is expected to grow at a CAGR of 8.763% during the forecast period from 2025 to 2035.

    What are the projected market values for Non-Proliferative Diabetic Retinopathy (NPDR) in 2024 and 2035?

    The NPDR segment is valued at 162.0 USD Million in 2024 and is expected to grow to 406.0 USD Million by 2035.

    What is the expected market size for Proliferative Diabetic Retinopathy (PDR) in 2024 and 2035?

    The PDR segment is projected to be valued at 200.0 USD Million in 2024 and 506.0 USD Million in 2035.

    Who are the major players in the Japan Diabetic Retinopathy Market?

    Key players include Santen Pharmaceutical, Bayer, Novartis, Otsuka Pharmaceutical, and Eli Lilly among others.

    What is the dominant market segment in the Japan Diabetic Retinopathy Market?

    The Proliferative Diabetic Retinopathy (PDR) segment holds a significant share of the market.

    What are the key growth drivers for the Japan Diabetic Retinopathy Market?

    Rising diabetes prevalence and increasing awareness regarding the disease are major growth drivers.

    What challenges does the Japan Diabetic Retinopathy Market face?

    Challenges include high treatment costs and a lack of trained healthcare professionals.

    How is the current market scenario affecting the Japan Diabetic Retinopathy Market?

    Current market dynamics are fostering innovations and new treatments in the Japan Diabetic Retinopathy Market.

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Stories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials